Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | IL6ST | P40189 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 9/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856585 | 1.00 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL21435764 | 1.00 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL21435819 | 1.00 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL7151197 | 1.00 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL3856583 | 1.00 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL7406075 | 0.92 | PPARA (0.47) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL2206996 | 0.92 | PPARA (0.47) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL2560993 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL12287709 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 | |
| SCHEMBL19923283 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20220194924-A1 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-23 | — | — | US | disclosed |
| US-20220194924-A1 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-23 | — | — | US | disclosed |
| EP-3946288-A1 | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113727707-A | Substituted 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives as selective CDK12/13 inhibitors | 奥里吉恩发现科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3774768-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2021-02-17 | — | — | EP | disclosed |
| US-10894786-B2 | Substituted pyrazole derivatives as selective CDK12/13 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-01-19 | — | — | US | disclosed |
| WO-2020202001-A1 | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-10-08 | — | — | WO | disclosed |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | KNOBELSDORF JAMES ALLEN (US) | 2004-03-18 | — | — | US | disclosed |
| US-6617351-B1 | Amide, carbamate, and urea derivatives | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6596716-B2 | 2-propane-sulphonamide derivatives | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-6521605-B1 | Potentiating glutamate receptor function; treating such as psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-2000006176-A1 | AMIDOPHOSPHATE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006156-A1 | AMIDE, CARBAMATE, AND UREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | PPARA 1048/4885IL6ST 155/4885IDH1 1361/4885 |
| US-10894786-B2 | Substituted pyrazole derivatives as selective CDK12/13 inhibitors | CDK12, CDK13, CDK1 | PPARA 4186/4885IL6ST 3519/4885IDH1 1276/4885 |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | GRIN2A, GRIN2B, GABRE | PPARA 1677/4885IL6ST 992/4885IDH1 1647/4885 |
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | CDK1, CDK12, CDK13 | PPARA 4384/4885IL6ST 3949/4885IDH1 1631/4885 |
| US-20220194924-A1 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | CDK1, CDK12, CDK13 | PPARA 4384/4885IL6ST 3949/4885IDH1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.